Non-alcoholic Steatohepatitis (NASH) Models

Wild Mouse 750
Wild Mouse 750
Human Xenograft Models
Cell Derived Xenograft Models
Autoimmune Disease Models
Systemic Lupus Erythematosus ModelsMultiple Sclerosis ModelsRheumatoid Arthritis ModelsPsoriasis ModelsInflammatory Bowel Disease ModelsAtopic Dermatitis Models Asthma Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsNon-alcoholic Steatohepatitis (NASH) ModelsHyperlipidemia ModelsOsteoporosis ModelsHyperuricemia Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765
Rare Disease Mouse Models
Progressive Muscular Dystrophy ModelsHemophilia A Models
Neurodegenerative Disease Mouse Models
Alzheimer’s Disease (AD) ModelsParkinson’s Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) Models
Immuno-Oncology Mouse Models
Human Xenograft ModelsHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models

Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat accumulates in the liver of patients with no history of alcoholism. Non-alcoholic steatohepatitis (NASH) is a more severe form of NAFLD, which manifests as liver steatosis and is accompanied by intralobular inflammation, hepatocellular ballooning, and even fibrosis. Preclinical studies using animal models are indispensable for developing novel anti-NASH drugs. GemPharmatech has developed a series of diet- or genetic mutation-induced NASH mouse models for preclinical drug efficacy tests.

NASH.png


Suggested Model: B6-Alms1-del NASH

ALMS1 is a gene connected with human Alström syndrome, and mutations/deletions in this gene are linked to metabolic disorders such as childhood obesity, developmental delay, hyperlipidemia, cardiomyopathy, and type II diabetes. Using gene editing technology, GemPharmatech induced an 11-bp base deletion in a specific sequence of exon 8 of the murine-derived Alms1 gene, resulting in premature termination of mouse Alms1 gene translation and generating an Alms1 mutant mouse model with a combined phenotype of obesity, diabetes, and NAFLD. When fed a conventional diet (CD), it develops obesity and moderate hyperglycemia with age and progressively increases hyperlipidemia and liver damage. The Western diet (WD) accelerated the development of metabolic disorders and liver damage. In comparison to the BKS-db NASH model, the B6-Alms1-del NASH model has moderate liver fibrosis and can be used to evaluate the therapeutic efficacy of anti-NASH medicines on liver fibrosis.

Case application

After 6 weeks of Western diet induction, B6-Alms1-del mice were randomly divided into 3 groups based on ALT index, and the solvent, MGL-3196, and semaglutide were administered to each group, respectively, with the Western diet to evaluate drug efficacy in the mice. B6J mice were given solvent and CD as a vehicle group.

image.png

MGL-3196 and Semaglutide ameliorated the steatosis and fibrosis phenotypes of B6-Alms1-del mice and lowered the disease score to some degree.


More efficacy data→

Strain No.
 Strain Name Strain Type Description
T017633 B6-Alms1-del(c.3802-3812) KO(TM) An 11-bp base deletion in exon 8 of the Alms1 gene in C57BL/6JGpt mice led to early termination of translation of the Alms1 gene, leading to a combined phenotype of obesity, early diabetes and non-alcoholic fatty liver disease. These mice are ideal models for studies on obesity and fatty liver.
T002407 BKS-db KO C57BLKS/JGpt mice lacking the Lepr gene develop severe morbid obesity, significant and persistent increase in blood glucose, islet damage and atrophy, severe insulin resistance, severe diabetic nephropathy, and diabetic retinopathy. These mice are ideal models for studying Type II diabetes and related complications.